SNRI — active O-desmethyl metabolite of venlafaxine. Bypasses CYP2D6 conversion → more consistent levels in CYP2D6 poor metabolizers. Stronger NE component at therapeutic doses than venlafaxine.
Half-Life & Elimination Curve (PO: 11h)
Plasma (PO)t½ Decay (11h)
0×t½0h100%(0.101 mg/L)
1×t½11h50%(50.3 µg/L)
2×t½22h25%(25.1 µg/L)
3×t½33h12.5%(12.6 µg/L)
4×t½44h6.3%(6.29 µg/L)
5×t½55h3.1%(3.14 µg/L)
Elimination t½11h (PO)
Rate Constant (ke)0.063 h⁻¹
Time to Peak (Tmax)7.37h
Est. Peak (Cmax)0.101 mg/L
Clearance (CL)15.8 L/h
97% Washout (5×t½)55h
Dosing Guidelines
Oral (PO): Typical 50 mg (Range: 50–100 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 80% · Volume of Distribution (Vd): 250 L · Absorption (ka): 0.25 h⁻¹ (t½ka ≈ 2.77h) [PMID 19698900]